JP2022520832A5 - - Google Patents

Info

Publication number
JP2022520832A5
JP2022520832A5 JP2021547546A JP2021547546A JP2022520832A5 JP 2022520832 A5 JP2022520832 A5 JP 2022520832A5 JP 2021547546 A JP2021547546 A JP 2021547546A JP 2021547546 A JP2021547546 A JP 2021547546A JP 2022520832 A5 JP2022520832 A5 JP 2022520832A5
Authority
JP
Japan
Application number
JP2021547546A
Other languages
Japanese (ja)
Other versions
JP2022520832A (ja
JP7571037B2 (ja
JPWO2020165838A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/051210 external-priority patent/WO2020165838A1/en
Publication of JP2022520832A publication Critical patent/JP2022520832A/ja
Publication of JPWO2020165838A5 publication Critical patent/JPWO2020165838A5/ja
Publication of JP2022520832A5 publication Critical patent/JP2022520832A5/ja
Priority to JP2024177283A priority Critical patent/JP2025004186A/ja
Application granted granted Critical
Publication of JP7571037B2 publication Critical patent/JP7571037B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547546A 2019-02-15 2020-02-13 眼表面疼痛を治療する方法 Active JP7571037B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177283A JP2025004186A (ja) 2019-02-15 2024-10-09 眼表面疼痛を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806682P 2019-02-15 2019-02-15
US62/806,682 2019-02-15
PCT/IB2020/051210 WO2020165838A1 (en) 2019-02-15 2020-02-13 Methods for treating ocular surface pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177283A Division JP2025004186A (ja) 2019-02-15 2024-10-09 眼表面疼痛を治療する方法

Publications (4)

Publication Number Publication Date
JP2022520832A JP2022520832A (ja) 2022-04-01
JPWO2020165838A5 JPWO2020165838A5 (https=) 2023-02-21
JP2022520832A5 true JP2022520832A5 (https=) 2023-02-21
JP7571037B2 JP7571037B2 (ja) 2024-10-22

Family

ID=69740423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547546A Active JP7571037B2 (ja) 2019-02-15 2020-02-13 眼表面疼痛を治療する方法
JP2024177283A Pending JP2025004186A (ja) 2019-02-15 2024-10-09 眼表面疼痛を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177283A Pending JP2025004186A (ja) 2019-02-15 2024-10-09 眼表面疼痛を治療する方法

Country Status (17)

Country Link
US (4) US20200261456A1 (https=)
EP (1) EP3923909A1 (https=)
JP (2) JP7571037B2 (https=)
KR (1) KR20210129677A (https=)
CN (1) CN113453686B (https=)
AU (2) AU2020222348B2 (https=)
BR (1) BR112021015998A2 (https=)
CA (1) CA3130038A1 (https=)
CL (1) CL2021002152A1 (https=)
IL (1) IL284629A (https=)
JO (1) JOP20210217A1 (https=)
MX (2) MX2021009702A (https=)
PH (1) PH12021551968A1 (https=)
SG (1) SG11202107260VA (https=)
TW (2) TW202515576A (https=)
WO (1) WO2020165838A1 (https=)
ZA (1) ZA202104593B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
WO2022029656A1 (en) * 2020-08-06 2022-02-10 Novartis Ag Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
CN119184616A (zh) * 2024-09-03 2024-12-27 中山大学附属第三医院粤东医院(梅州市梅县区人民医院) 一种疼痛等级的测评方法及其评估系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US7893260B2 (en) 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
BRPI0620264A2 (pt) 2005-12-22 2011-11-08 Prolexys Pharmaceuticals Inc quinazolonas aril-substituìdas e sua utilização
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
AR067631A1 (es) 2007-07-18 2009-10-21 Novartis Ag Combinaciones sinergicas de antagonistas de vr-1 e inhibidores de cox-2 , composicion farmaceutica y uso
TW200927192A (en) * 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
CA2707441A1 (en) 2008-01-09 2009-07-16 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
US9827225B2 (en) * 2016-01-25 2017-11-28 Jenivision Inc. Use of prostacyclin antagonists for treating ocular surface nociception
US10590077B2 (en) 2016-09-20 2020-03-17 Glaxosmithkline Intellectual Property Development Limited TRPV4 antagonists
CN109790116B (zh) 2016-09-20 2022-10-28 葛兰素史密斯克莱知识产权(第2 号)有限公司 Trpv4拮抗剂
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產(第二)有限公司 Trpv4拮抗劑
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
JP2022520410A (ja) * 2019-02-15 2022-03-30 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの結晶形態及びその製剤

Similar Documents

Publication Publication Date Title
CN305536200S (https=)
CN305580511S (https=)
CN305536623S (https=)
CN305539862S (https=)
CN305541126S (https=)
CN305542213S (https=)
CN305537233S (https=)
CN305649225S (https=)
CN305532572S (https=)
CN305656029S (https=)
CN305665517S (https=)
CN305696499S (https=)
CN305703361S (https=)
CN305746351S (https=)
CN305746792S (https=)
CN305747827S (https=)
CN305809576S (https=)
CN305809905S (https=)
CN305821570S (https=)
CN305821758S (https=)
CN305833321S (https=)
CN305844801S (https=)
CN305857630S (https=)
CN305893527S (https=)
CN305901389S (https=)